1. Home
  2. ALRN vs MCHX Comparison

ALRN vs MCHX Comparison

Compare ALRN & MCHX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALRN
  • MCHX
  • Stock Information
  • Founded
  • ALRN 2001
  • MCHX 2003
  • Country
  • ALRN United States
  • MCHX United States
  • Employees
  • ALRN N/A
  • MCHX N/A
  • Industry
  • ALRN Biotechnology: Pharmaceutical Preparations
  • MCHX Business Services
  • Sector
  • ALRN Health Care
  • MCHX Consumer Discretionary
  • Exchange
  • ALRN Nasdaq
  • MCHX Nasdaq
  • Market Cap
  • ALRN 76.9M
  • MCHX 84.3M
  • IPO Year
  • ALRN 2017
  • MCHX 2004
  • Fundamental
  • Price
  • ALRN $1.97
  • MCHX $1.92
  • Analyst Decision
  • ALRN Strong Buy
  • MCHX
  • Analyst Count
  • ALRN 1
  • MCHX 0
  • Target Price
  • ALRN $19.00
  • MCHX N/A
  • AVG Volume (30 Days)
  • ALRN 137.2K
  • MCHX 31.7K
  • Earning Date
  • ALRN 11-14-2024
  • MCHX 03-13-2025
  • Dividend Yield
  • ALRN N/A
  • MCHX N/A
  • EPS Growth
  • ALRN N/A
  • MCHX N/A
  • EPS
  • ALRN N/A
  • MCHX N/A
  • Revenue
  • ALRN N/A
  • MCHX $48,594,000.00
  • Revenue This Year
  • ALRN N/A
  • MCHX N/A
  • Revenue Next Year
  • ALRN N/A
  • MCHX $4.63
  • P/E Ratio
  • ALRN N/A
  • MCHX N/A
  • Revenue Growth
  • ALRN N/A
  • MCHX N/A
  • 52 Week Low
  • ALRN $1.61
  • MCHX $1.11
  • 52 Week High
  • ALRN $7.42
  • MCHX $2.40
  • Technical
  • Relative Strength Index (RSI)
  • ALRN 41.44
  • MCHX 48.44
  • Support Level
  • ALRN $1.90
  • MCHX $1.88
  • Resistance Level
  • ALRN $2.17
  • MCHX $2.13
  • Average True Range (ATR)
  • ALRN 0.18
  • MCHX 0.11
  • MACD
  • ALRN 0.02
  • MCHX -0.01
  • Stochastic Oscillator
  • ALRN 23.27
  • MCHX 46.15

About ALRN Aileron Therapeutics Inc.

Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. The company currently has two product candidates in clinical development, LTI-03 and LTI-01, and multiple candidates in preclinical development focused on fibrosis indications.

About MCHX Marchex Inc. Class B

Marchex Inc is a conversational analytics and solutions company that helps businesses connect, drive, measure, convert callers into customers, and connect the voice of the customer to their business. It delivers data insights and incorporates artificial intelligence (AI)-powered functionality that drives insights and solutions to help companies find, engage, and support their customers across voice and text-based communication channels. The group enables sales and marketing teams to deliver the buying experiences that today's customers expect. The company generates the majority of its revenues from core analytics and solutions services. The company operates in the United States, Canada, and other countries.

Share on Social Networks: